Corporate Action, Amendments to Bylaws (Form 8-K)

The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

As previously disclosed by Curanex Pharmaceuticals Inc (the "Company"), on May 31, 2026, the board of directors of the Company (the "Board") approved by unanimous written consent, and on June 11, 2026, holders of a majority of the outstanding voting power of the Company, acting by written consent, in accordance with the applicable provisions of the Nevada Revised Statutes ("NRS") and the Company's Amended and Restated Articles of Incorporation, as amended (the "Articles of Incorporation"), and its Bylaws, approved a reverse stock split of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of not less than 1-for-10 and not more than 1-for-50 (the "Reverse Split Range") and a form of a Certificate of Amendment to the Articles of Incorporation (the "Certificate of Amendment"), and granted the Board the discretionary authority to determine the exact ratio of a reverse stock split within the Reverse Split Range and to effect a reverse stock split at such time and date, if at all, as to be determined by the Board in its sole discretion. On July 22, 2026, the Board approved, by unanimous written consent, a 1-for-20 reverse stock split (the "Reverse Stock Split") of the issued and outstanding shares of the Company's Common Stock.

On August 14, 2026, the Company filed the Certificate of Amendment with the Nevada Secretary of State in accordance with NRS 78.390, to become effective at 12:01 a.m. Pacific Time on August 20, 2026 (the "Effective Time"), implementing the Reverse Stock Split. After the Effective Time, it is expected the Common Stock will begin trading on Nasdaq on a reverse split-adjusted basis when the market opens on August 20, 2026, under the existing trading symbol "CURX" but having a new CUSIP number.

At the Effective Time, every 20 shares of Common Stock issued and outstanding will be automatically converted into one (1) issued and outstanding share of Common Stock, resulting in approximately 1,568,241 shares of Common Stock, subject to adjustments (based on 31,364,812 shares of Common Stock outstanding immediately prior to the Effective Time). The total number of shares of Common Stock authorized for issuance, 475,000,000 shares, and the par value per share of the Common Stock, $0.0001 will remain unchanged.

In addition, as a result of the effectiveness of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of Common Stock underlying the Company's outstanding equity awards under the Company's 2026 Equity Incentive Plan as well as the exercise and grant prices of such equity awards, as applicable. The total number of shares of the Company's preferred stock, par value $0.0001 per share, authorized for issuance will remain at 25,000,000. Furthermore, no change will be made to the number of issued and outstanding shares of the Company's Series A Preferred Stock, par value $0.0001 per share.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will be entitled to have such fractional share rounded up to the nearest whole share and, as such, any stockholder who otherwise would have held a fractional share after giving effect to the Reverse Stock Split will instead hold one whole share of Common Stock. No cash or other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Stock Split. VStock Transfer, LLC, the Company's transfer agent, is acting as the exchange agent for the Reverse Stock Split and will provide instructions to stockholders of record regarding the process for exchanging shares.

The purpose of effecting the Reverse Stock Split is to regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq.

The foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the form of Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.